BLCM News and Press, Bellicum Pharmaceuticals Inc. From 05/08/23

2023-05-08 08:19:51 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immuron (NASDAQ: IMRN ) stock is gaining on Monday thanks to an update from the Food and Drug Administration (FDA) on a clinical hold. The FDA has lifted a clinical hold ...

2023-05-08 07:51:24 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bellicum Pharmaceuticals (NASDAQ: BLCM ) stock is rising higher on Monday morning following news of an investment in the company . According to a filing with the Securit...

2023-05-08 07:31:36 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are a hot topic on Monday as we dive into the biggest winners and losers this morning! Moving stocks this morning are investments, regulatory updates, and more. ...

HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavi...

Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients PSA50 or greater responses in 50% of patients Responses observed in patients with visceral, nodal and b...

HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not 45,000, as previously stated. The corrected release follows: Bellicum Pharmaceuticals, Inc. (N...

HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T ® produ...

HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster presentation by the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberg...

Bellicum Pharmaceuticals press release ( NASDAQ: BLCM ): Q3 GAAP EPS of -$0.23. Revenue of $1M. Bellicum reported cash and cash equivalents totaling $28.8 million as of September 30, 2022, compared to cash, cash equivalents and restricted cash totaling $47.7 million as...

HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2022 and provided an operational update. “We are enc...